A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.
Allergan conducted the trial to evaluate the duration of effect and safety of Botox Cosmetic 40, 60, and 80 unit doses versus Botox Cosmetic 20 unit dose in 226 patients.
In the trial, 32% of patients were responders at week 24 in the Botox Cosmetic 40 unit group, 30.6% in the 60 unit group, and 38.5% in the 80 unit group, compared to 16% in the 20 unit group.
"These study results help us better understand the Botox Cosmetic dose duration of effect and confirm our hypothesis that higher doses of botulinum toxin produce a longer duration of treatment effect for the treatment of glabellar lines," said David Nicholson, chief research and development officer, Allergan. "Based on this data, doubling the dose of botulinum toxin extends the duration of effect to 24 weeks in approximately one-third of patients."